Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People who have been diagnosed with a high-grade blood cancer involving the bone marrow (with at least 10% abnormal cells in the blood or bone marrow), a type of blood cancer called acute myeloid leukemia (AML, but not a specific subtype called APL), or a type of blood and lymph cancer called B-cell acute lymphoblastic lymphoma/leukemia (ALL), as classified by 2022 medical guidelines
- People who are planning to receive intensive chemotherapy or a stem cell transplant from a donor, where the treatment is expected to lower red blood cell and platelet levels significantly for at least 5 days (as assessed by the lead trial doctor)
- People who plan to receive all of their care after chemotherapy or stem cell transplant at the University of Washington or Fred Hutchinson Cancer Center
- People who are able to understand and willing to sign a written consent form
Who may not be able to join:
- People who require platelet transfusions at levels higher than a specific threshold (above 10,000 per microlitre) as a preventive measure
- People who need blood-thinning or clot-preventing medications that cannot be paused when platelet levels drop below a certain point
- People who are experiencing significant bleeding (grade 2 or higher based on a standard medical scale) at the time of joining the trial
- People who have had a blood clot, stroke-related blood vessel event, or heart attack within the 6 months before starting chemotherapy or a stem cell transplant
- People who are on kidney dialysis or another form of kidney replacement therapy at the time of joining the trial
- People who decline blood transfusions due to personal or religious beliefs
- People who are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Anna Halpern, MD, Fred Hutch/University of Washington Cancer Consortium
Phone: 206-606-1978
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of eligible patients that consent (feasibility); Percentage of patients randomized to the restrictive 7 gm/dL threshold that tolerate this transfusion trigger (feasibility); Indication for early termination based on interim analyses of safety (feasibility)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.